Clinical Medicine · 2020 · 28 citations · 16 references
MedicineInternal MedicinePathologyHepatologyMolecular PathologyChronic Liver DiseaseCirrhosisHepatic FibrosisHepatic PathologyLiver DiseaseMetabolic Liver DiseaseNonalcoholic Fatty Liver Disease-associated Insulin ResistanceNonalcoholic Steatohepatitis Associated FibrosisNonalcoholic Steatohepatitis Cirrhosis
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. NAFLD is defined by excess fat in the liver and has a multidirectional relationship with metabolic syndrome. The prevalence of NAFLD has risen rapidly in recent years in line with the obesity epidemic and associated increases in type 2 diabetes, hypertension and hypercholesterolaemia. Patients with NAFLD are at risk of cardiovascular disease and cancer, and in a proportion of individuals, NAFLD is associated with liver damage. This article summarises the epidemiology of NAFLD, the clinical approach to risk-assessing patients and briefly outlines current and future management options.
16
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal, Naga Chalasani, Kris V. Kowdley et al. · New England Journal of Medicine · 2010 · 3.3K citations · Full text
Christopher D. Williams, Joel Z. Stengel, Michael Asike et al. · Gastroenterology · 2010 · 2.2K citations · Full text
Matthew J. Armstrong, Piers Gaunt, Guruprasad P. Aithal et al. · The Lancet · 2015 · 2.1K citations · Full text